Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma

Blood Adv. 2019 Mar 12;3(5):766-768. doi: 10.1182/bloodadvances.2018026351.

Abstract

  1. Brentuximab vedotin is active in primary effusion lymphoma, a rare CD30-positive lymphoma with an extremely poor prognosis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology
  • Brentuximab Vedotin / pharmacology*
  • Brentuximab Vedotin / therapeutic use
  • Humans
  • Ki-1 Antigen / metabolism
  • Lymphoma, AIDS-Related / drug therapy*
  • Lymphoma, Primary Effusion / drug therapy*
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Ki-1 Antigen
  • Brentuximab Vedotin